Kura Oncology, Inc. KURA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-2.37
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $67.5M | -$278.7M | — | -$70.7M | $174.1M |
| 2024 | $53.9M | -$174.0M | — | $133.8M | $413.6M |
| 2023 | $0 | -$152.6M | — | -$125.0M | $397.3M |
| 2022 | — | -$135.8M | — | -$110.7M | $420.3M |
| 2021 | — | -$130.5M | — | -$105.7M | $506.6M |
| 2020 | — | -$89.6M | — | -$72.0M | $610.9M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Leoni Mollie | Chief Medical Officer | 2026-06-18 | Sell | 84,929 | $9.82 |
| Powl Brian T. | Chief Commercial Officer | 2026-05-21 | Sell | 10,000 | $11.00 |
| Powl Brian T. | Chief Commercial Officer | 2026-05-19 | Sell | 339 | $9.21 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.37 (distress)
- Working capital / assets 0.801
- Retained earnings / assets -1.59
- EBIT / assets -0.411
- Equity / liabilities 0.309
Source: SEC EDGAR filings · CIK 0001422143 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.